We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Urotensin II in Chronic Kidney Diseases and Kidney Transplants

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01098799
First Posted: April 5, 2010
Last Update Posted: June 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mehmet Hursitoglu, Vakif Gureba Training and Research Hospital
  Purpose
The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.

Condition
Chronic Renal Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Urotensin II in Chronic Kidney Diseases

Resource links provided by NLM:


Further study details as provided by Mehmet Hursitoglu, Vakif Gureba Training and Research Hospital:

Primary Outcome Measures:
  • serum Urotensin II(UII)level [ Time Frame: at enrollment ]
    We tried to compare UII level in normal, chronic kidney disease and kidney transplant patients group


Enrollment: 110
Study Start Date: April 2010
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control
Healthy controls
Chronic kidney disease-1
Chronic kidney disease not taking dialysis treatment
Kidney Transplant
Kidney transplants

Detailed Description:
The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy controls,CRF patients and kidney transplants aged more than 18
Criteria

Inclusion Criteria:

  • Age more than 18

Exclusion Criteria:

  • Inability to give a written consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01098799


Locations
Turkey
Vakif Gureba Training & Research Hospital
Istanbul, Turkey, 34100
Sponsors and Collaborators
Vakif Gureba Training and Research Hospital
Investigators
Study Director: Tufan Tukek, MD Vakif Gureba Training & Research Hospital
  More Information

Responsible Party: Mehmet Hursitoglu, Chair, Vakif Gureba Training and Research Hospital
ClinicalTrials.gov Identifier: NCT01098799     History of Changes
Other Study ID Numbers: Dahiliye-2-Urotensin
First Submitted: April 2, 2010
First Posted: April 5, 2010
Last Update Posted: June 13, 2013
Last Verified: June 2013

Keywords provided by Mehmet Hursitoglu, Vakif Gureba Training and Research Hospital:
Urotensin II,Chronic renal disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency